Special points of interest

th
January 6 2015 FDA approved the release of Bellafill

B el la f i l l ()

Gen er ic N am e

Used for the treatment of: Severe facial acne scars in patients
21 years and older.
 Dosage: Injected under the skin to act as a collagen filler.
 Marketing Information from Manufacturer: The Bellafill
product is a mixture of purified bovine collagen and
polymethylmethacrylate (PMMA) microspheres. The collagen
puffs up the area where it’s injected, while the microspheres
provide a structure within which naturally produced collagen
can gather. In time, the injected collagen is replaced by the
patient’s own, providing natural long-term results. The
product has a proven safety record, having been approved for
treating nasolabial folds, or smile lines, since 2006.
 Benefits and Concerns of the Drug: It is primarily a cosmetic

.
d er m a l f il ler

Sunev a Medical, Inc.,
a privately -held
aesthetics company,
today announced that
ArteFill, a dermal
filler, has been
rebranded as Bell afill
in the U.S.
process which is expanded to include people with Acne Scars.
Coverage Recommendations: These recommendations are
available to IPC/EvergreenRx clients from their Account Manager or
Clinical Pharmacist.
T 636.614.1344
www.ipc-inc.com
A Brown & Brown company
Please contact us with any questions or comments
